- Conditions
- Diabetes Mellitus
- Interventions
- Albiglutide 30 mg, Albiglutide 50 mg, Albiglutide matching placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 9,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Hyperparathyroidism
- Interventions
- Denosumab, Placebo
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab SAR440340, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Fresno, California • Palm Springs, California + 49 more
- Conditions
- Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
- Interventions
- Halneuron, Placebo, Halneuron (Open Label Extension)
- Drug
- Lead sponsor
- Dogwood Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 25
- States / cities
- Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab, Placebo
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 40
- States / cities
- Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more
- Conditions
- Longevity, Preventive Medicine, Biological Ageing
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Atria Research and Global Health Institute (ARGHI)
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ASCVD, Elevated Cholesterol
- Interventions
- Inclisiran Sodium, Placebo
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
- Conditions
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Evolocumab, Atorvastatin, Placebo
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Indianapolis, Indiana + 8 more
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
- Interventions
- SBP-101, Nab-paclitaxel, Gemcitabine, Placebo
- Drug · Other
- Lead sponsor
- Panbela Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Hot Springs, Arkansas • Fullerton, California • New Haven, Connecticut + 11 more
- Conditions
- Infertility
- Interventions
- Follitropin delta, Placebo
- Drug · Other
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 23
- States / cities
- Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more
- Conditions
- Multiple Myeloma
- Interventions
- Ramantamig, Tocilizumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Goodyear, Arizona • Beverly Hills, California • Irvine, California + 6 more
- Conditions
- Psoriasis
- Interventions
- Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 837 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 26
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 23 more
- Conditions
- Hyperlipidaemia
- Interventions
- AZD8233, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Huntsville, Alabama • Canoga Park, California • Lincoln, California + 12 more
- Conditions
- Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
- Interventions
- Intra-lymphatic allergenic extract, Intra-lymphatic placebo
- Biological
- Lead sponsor
- Christopher Thompson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Austin, Texas • Grapevine, Texas • San Antonio, Texas
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg, Golimumab 50 mg
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,065 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Roseville, California + 55 more
- Conditions
- Knee Osteoarthritis, Cartilage Degeneration
- Interventions
- Teriparatide, Placebo
- Drug
- Lead sponsor
- Christopher Ritchlin
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Asthma
- Interventions
- JNJ-95597528, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Westminster, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Chronic Cluster Headache
- Interventions
- Galcanezumab 300 mg, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Santa Monica, California • Stanford, California + 10 more
- Conditions
- Homocystinuria
- Interventions
- Pegtibatinase, Placebo
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 5 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
- Conditions
- Venous Thromboembolism
- Interventions
- Semuloparin sodium, Enoxaparin sodium, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- COVID-19
- Interventions
- Dupilumab, Placebo
- Biological · Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Atopic Dermatitis
- Interventions
- FB825 or Placebo in subcutaneous route, FB825 in intravenous route
- Drug
- Lead sponsor
- Oneness Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 654 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 45 more
- Conditions
- Polycythemia Vera
- Interventions
- SLN124, Placebo
- Drug
- Lead sponsor
- Silence Therapeutics plc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 5
- States / cities
- Hammond, Louisiana • Buffalo, New York • New York, New York + 2 more